Vaxart Q3 Revenue Falls to $10.6M; Cash Runway Into Q2 2027
VXRT is trading near its 52-week low of $0.32 (14% above the low).
Summary
Vaxart posted Q3 2026 revenue of $10.6M versus $72.4M a year earlier and a $17.7M net loss, with $65.5M in cash that it says lasts into Q2 2027 — short of the mid-2027 Phase 2b COVID-19 data readout.
Key Events · Earnings and Guidance · VXRT
-
Q3 Revenue Drops to $10.6M
Revenue fell from $72.4M in Q3 2025 to $10.6M in Q3 2026, primarily BARDA contract revenue, with Q3 2026 also including Dynavax license revenue.
-
Net Loss Widens to $17.7M
Net loss was $17.7M, or ($0.07) per share, versus $8.1M, or ($0.04) per share, a year earlier; R&D fell to $22.8M from $75.9M.
-
Cash Runway Into Q2 2027
Cash, cash equivalents and short-term investments totaled $65.5M at September 30, 2026, which management says funds operations into Q2 2027.
-
COVID Data Now Mid-2027
Topline efficacy and safety data from the 400-person sentinel cohort and roughly 5,000 main-cohort patients are now expected by mid-year 2027, after the stated runway ends.
Analysis · VXRT · Life Sciences
The revenue collapse to $10.6M from $72.4M a year ago reflects a heavy BARDA contract billing surge in the prior-year quarter, and the net loss widened to $17.7M from $8.1M. What matters most is the $65.5M of cash and investments, which management says funds operations only into the second quarter of 2027 — before the Phase 2b COVID-19 topline readout now guided to mid-year 2027. That gap means another raise or a partnership is likely needed to reach the data, and the company says it is pursuing business development and non-dilutive funding. The $49.7M at-the-market program established in May 2026 remains the most obvious dilution channel.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VXRT was trading at $0.37 on OTC in the Life Sciences sector, with a market capitalization of approximately $88.6M. The 52-week trading range was $0.32 to $0.84. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.